What were the results of the study by Berger et al. (2010) regarding natruiretic peptide monitoring?
Berger et al. (2010) found that NP monitoring is cost effective for patients with chronic heart failure and LVSD at any age compared to specialist management [ICER: 3,304 per QALY gained]. The probability that NP monitoring is cost effective at the 20,000 threshold was 99%. Similar results were found for patients with CHF and LVSD <75 years old [ICER: 2,871 per QALY gained] with a 98% probability of being cost effective at the 20,000 threshold. NP monitoring was also found to be cost effective in patients with CHF and LVSD 75 years old [ICER: 5,392 per QALY gained], however this is uncertain as there is only a 68% probability that NP monitoring is cost effective at the 20,000 threshold.